Hunt joins DeSilva & Phillips' medical media group

Charlie Hunt has joined investment bank DeSilva & Phillips as managing director of its healthcare and medical media group.  For the last seven years, this group has been led by managing director Pres Williams, who will take a less active role as a senior advisor, according to a statement issued by the firm this week.
Working with Williams, Desilva & Phillips had an unparalleled record of 24 transactions with publications and publishers, continuing medical education companies and market research companies.
Hunt was formerly president of PERQ/HCI Research, the healthcare research division of VNU. He earned the title after serving as general manager of VNU's PERQ Research and its Interactive Market Systems. Hunt also was publisher of Physicians' Travel & Meeting Guide magazine at Cahners Medical Publishing, group publisher at PW Communications, and a publisher at the Medical Economics Company. He is a graduate of Cornell University, and entered the pharmaceutical marketing world as a detail sales representative at Warner Lambert, where he rose to become division manager, sales for the general diagnostic division.
You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.